Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis

Johannes F.E. Mann(Katholische Stiftungshochschule München), Vlado Perkovic(New South Wales Department of Health), Benjamin Ole Wolthers(Novo Nordisk (Denmark)), Lawrence A. Leiter(St. Michael's Hospital), Richard E. Pratley(Translational Research Institute for Metabolism and Diabetes), Søren Rasmussen(Novo Nordisk (Denmark)), Tina Vilsbøll(University of Copenhagen), Thomas Idorn(University of Copenhagen), John B. Buse(Unknown)
Diabetes Obesity and Metabolism
May 19, 2021
10.1111/dom.14443
Cited by 105

Related Papers

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
|Diabetes Care|2018|3.5k